Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
61-80 of 1,743 trials

Ovarian Cancer Treatment: Carboplatin and Mirvetuximab Soravtansine

We are studying a combination of carboplatin and a new drug, Mirvetuximab soravtansine, for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy. This trial aims to see if this treatment improves response rates in patients with specific tumor characteristics.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Rod Cone Dystrophy: SPVN06 Gene Therapy

We are evaluating the safety and tolerability of a new gene therapy for patients with rod cone dystrophy. This study aims to understand how well the treatment is tolerated in this specific group.

Hereditary Retinal Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)Ophthalmology

Cancer Treatment: Long-term Study of Pembrolizumab

We are evaluating the long-term safety and survival of patients currently on pembrolizumab treatment. This study aims to understand how well the treatment works and its effects over time.

Advanced Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Rituximab for Progressive Interstitial Lung Disease

We are studying whether rituximab can improve lung function in patients with progressive interstitial lung disease. This trial compares its effects to a placebo to assess safety and quality of life.

Interstitial Lung Disease>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Severe Eosinophilic Asthma: Benralizumab for Kids

We are studying whether benralizumab can help children with severe eosinophilic asthma by reducing asthma attacks and improving their symptoms. This trial will also look at the safety of the medication.

Severe Eosinophilic Asthma>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyPulmonology

Axial Spondyloarthritis: Filgotinib Study

We are testing the medication filgotinib in adults with active axial spondyloarthritis to see if it improves symptoms and physical function compared to a placebo. The study also looks at the safety of this treatment.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Acute Myeloid Leukemia: Oral-Azacitidine with Gilteritinib

We are studying a new combination treatment for adults with relapsed or refractory FLT3-mutated acute myeloid leukemia. The goal is to see if this approach improves remission rates and safety compared to current options.

Acute Myeloid Leukaemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Myeloid Diseases: DFV890 Treatment Study

We are investigating the safety and effectiveness of DFV890 in adults with myeloid diseases. This study aims to understand how well this treatment works and how it is tolerated.

Myeloid Dysplasia>2 yearsSafety phase (I)HematologyOncology

Heart Attack Recovery: Milvexian Study

We are testing a new oral medication, milvexian, to see if it helps reduce the risk of further heart problems in patients after a heart attack. This study compares milvexian to a placebo alongside standard treatment.

Acute Coronary Syndrome>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Breast Cancer: Elacestrant vs. Standard Therapy

We are studying whether elacestrant can help women with ER+/HER2- breast cancer who have signs of relapse delay cancer spread compared to standard treatments. The trial also looks at safety and how patients feel about the treatment.

Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

ALK-Positive Anaplastic Large Cell Lymphoma: Vinblastine Treatment

We are studying whether Vinblastine can effectively treat children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma. The goal is to see if it can cure at least 75% of these patients.

ALK-positive Anaplastic Large Cell Lymphoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesOncologyPediatrics

Atypical Teratoid/Rhabdoid Tumors: High-Dose Chemotherapy vs. Radiotherapy

We are studying whether high-dose chemotherapy is as effective as radiotherapy for young children with ATRT. This trial aims to improve treatment options and understand the long-term effects on health and quality of life.

Atypical Teratoid/Rhabdoid Tumors (ATRT)>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Advanced Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab Study

We are studying whether a combination of Fianlimab and Cemiplimab is more effective than Cemiplimab alone for adults with advanced non-small cell lung cancer. This trial focuses on patients whose tumors express PD-L1 at high levels.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Standard MedicinesPartially RemoteOncology

Hypertension in Chronic Kidney Disease: Diuretic Treatment Study

We are investigating if a new diuretic-based treatment helps people with moderate to severe chronic kidney disease and uncontrolled hypertension. The goal is to see if it can reduce serious health issues like kidney failure and heart problems.

Chronic Kidney DiseaseUncontrolled Hypertension>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyNephrology

Multiple Myeloma: Iberdomide vs. Lenalidomide Maintenance Therapy

We are comparing two treatments for newly diagnosed multiple myeloma patients after stem cell transplant to see which one may help keep the disease from worsening. This study will also look at safety and quality of life for participants.

Newly Diagnosed Multiple Myeloma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Prostate Cancer: Surgery with Darolutamide

We are studying whether adding darolutamide before and after surgery helps improve survival and quality of life for patients with high-risk or locally advanced prostate cancer.

Prostate Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Breast Cancer: Ribociclib with Hormone Therapy and Radiotherapy

We are studying the safety and effectiveness of Ribociclib combined with hormone therapy and radiotherapy for elderly patients with hormone-positive, HER2-negative breast cancer. This trial is for those newly diagnosed who are not ready for surgery.

Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Osimertinib (TAGRISSO) Continuation Study

We are providing ongoing treatment with osimertinib for patients who have benefited from it in a previous study. The goal is to monitor safety and tolerability as they continue their treatment.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Corticosteroid Treatment for Acute Myocarditis

We are studying whether intravenous corticosteroids can improve heart function in patients with acute myocarditis and mildly reduced heart performance. This trial compares corticosteroid therapy to standard treatment options.

Acute Myocarditis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Dupuytren Contracture: Needle Procedure with Corticosteroid Injection

We are comparing a needle procedure with a corticosteroid injection to one with a saline injection for Dupuytren Contracture in the hand. This study aims to see if the corticosteroid helps reduce the chance of the condition returning.

Dupuytren's Contracture>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesDermatologyOrthopedics and Traumatology